MedWatch

Genmab says new arbitration builds on a straightforward question

”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.

Photo: Joost Melis / Genmab / PR

Having lost an arbitration case against its partner Janssen in April, Genmab chose to bring a new suit against the company based on the earlier ruling.

The Danish biotech company’s chief executive, Jan van de Winkel, chooses his words carefully when commenting on the legal strife and the time horizon for when he expects it to conclude, although the legal question itself is easier to speak about:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs